Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

Leuk Lymphoma. 2016 Sep;57(9):2228-31. doi: 10.3109/10428194.2015.1132419. Epub 2016 Jan 13.

¹ a US Oncology Research, Inc. , The Woodlands , TX , USA ;
² b Indiana University Cancer Center , Indianapolis , IN , USA ;
³ c Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
⁴ d Division of Hematology-Oncology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA ;
⁵ e Maryland Oncology Hematology , Columbia , MD , USA ;
⁶ f Providence Cancer Center Institute, Southfield , MI , USA ;
⁷ g Division of Cellular Therapy , Duke University Medical Center , Durham , NC , USA ;
⁸ h Steeplechase Cancer Center , Somerville , NJ , USA ;
⁹ i Epidemiology and Biostatistics, University of South Carolina , Columbia , SC , USA ;
¹⁰ j Celgene Corporation , Summit , NJ , USA ;
¹¹ k Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute , Los Angeles , CA , USA.

No abstract available

Publication types